Molecular Targeting Technologies (MTTI) and Brookline Capital Markets are collaborating at the 2nd Targeted Radionuclide Pharmaceuticals (TRPs) Supply Chain & Manufacturing Summit, held in Boston from September 24-26, 2024.
MTTI will present a workshop titled “Evaluating the Commercial & Pharmaceutical Viability of Radioisotopes to Benchmark Potential,” focusing on the emerging radiopharmaceutical market and its investment prospects.
Industry experts will discuss commercial and pharmaceutical challenges in developing radioisotopes such as actinium-225, lutetium-177, lead-212, and copper-67. They will explore topics like:
– Market demand assessment and commercial viability
– Navigating radiopharmaceutical development challenges
– Strategic partnerships and investment opportunities
Chris Pak, CEO of MTTI, highlighted the advantages of MTTI’s EB technology in overcoming challenges in TRPs. With 8 to 30-fold higher uptake at the target than standard TRPs, their patented platform offers improved efficacy and medical economics while requiring only 40% of the radiation dose.
The summit aims to enhance radiopharmaceutical production to meet the growing demand and address challenges in isotope production, radiolabeling, quality control, and supply chain logistics. It will provide valuable insights from leading companies in optimizing manufacturing processes and accelerating clinical trials.
MTTI, a clinical-stage company, is focused on developing novel targeted radiotherapeutics for rare cancers with high unmet needs. Their pipeline includes EBTATE® for neuroendocrine tumors, Hürthle cell thyroid cancer, nasopharyngeal cancer, small cell lung cancer, and EBRGD™ for non-small cell lung cancer and glioblastoma multiforme.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
